Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest announcement is out from Renalytix AI ( (GB:RENX) ).
Renalytix announced that its Chief Technology Officer and Executive Director, Fergus Fleming, has purchased 25,000 shares in the company, demonstrating confidence in its operations and market positioning. This transaction highlights the company’s ongoing commitment to addressing the significant challenge of chronic kidney disease, with its kidneyintelX.dkd tool already showing a substantial impact in improving diagnosis and treatment rates.
More about Renalytix AI
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing the clinical management of kidney disease to improve patient outcomes. The company has developed kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic tool for early-stage kidney disease risk assessment, which is being deployed in the United States.
YTD Price Performance: -46.67%
Average Trading Volume: 4,266
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $39.3M
For an in-depth examination of RENX stock, go to TipRanks’ Stock Analysis page.
